Cardiology Division, Department of Medicine; Department of Veterans Affairs, VA Long Beach Healthcare System, 5901 East 7th Street, Long Beach, CA 90822, USA.
Evidence-Based Practice Program, Veterans Health Administration, 811 Vermont Avenue, Northwest, Washington, DC 20420, USA.
Nurs Clin North Am. 2023 Sep;58(3):295-308. doi: 10.1016/j.cnur.2023.05.002. Epub 2023 Jun 15.
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States. The development and progression of atherosclerotic CVD are largely dependent on a multitude of modifiable and nonmodifiable risk factors. Current therapeutic strategies involve risk factor modification, especially dyslipidemia. The treatment of dyslipidemia continues to be dynamic, and in this paper, we review the current strategies for risk assessment, diagnosis, and treatment. As treatments for the management of dyslipidemia continue to evolve with ever-increasing options for therapeutic targets, an understanding of lipid-lowering therapies remains an essential topic of understanding for all health care providers.
心血管疾病（CVD）是美国发病率和死亡率的主要原因。动脉粥样硬化性 CVD 的发展和进展在很大程度上取决于多种可改变和不可改变的危险因素。目前的治疗策略包括危险因素的改变，特别是血脂异常。血脂异常的治疗仍然是动态的，在本文中，我们回顾了风险评估、诊断和治疗的当前策略。随着治疗血脂异常的方法不断发展，治疗靶点的选择也越来越多，因此，了解降脂治疗仍然是所有医疗保健提供者必须理解的一个重要课题。
